This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Feb 1;13(3):1068; author reply 1068-9.

doi: 10.1158/1078-0432.CCR-06-1715.

HDAC inhibitors and cardiac safety

Rhoda Molife, Peter Fong, Michelle Scurr, Ian Judson, Stan Kaye, Johann de Bono

PMID: 17289905
DOI: 10.1158/1078-0432.CCR-06-1715

Comment

HDAC inhibitors and cardiac safety

Rhoda Molife et al. Clin Cancer Res. 2007.

. 2007 Feb 1;13(3):1068; author reply 1068-9.

doi: 10.1158/1078-0432.CCR-06-1715.

Authors

Rhoda Molife, Peter Fong, Michelle Scurr, Ian Judson, Stan Kaye, Johann de Bono

PMID: 17289905
DOI: 10.1158/1078-0432.CCR-06-1715

No abstract available

PubMed Disclaimer

Comment on

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever M. Shah MH, et al. Clin Cancer Res. 2006 Jul 1;12(13):3997-4003. doi: 10.1158/1078-0432.CCR-05-2689. Clin Cancer Res. 2006. PMID: 16818698 Clinical Trial.

Similar articles

Histone deacetylase inhibitors in cancer therapy.
Fouladi M. Fouladi M. Cancer Invest. 2006 Aug-Sep;24(5):521-7. doi: 10.1080/07357900600814979. Cancer Invest. 2006. PMID: 16939962 Review. No abstract available.
Inhibitors of histone deacetylase as new anticancer agents.
Jung M. Jung M. Curr Med Chem. 2001 Oct;8(12):1505-11. doi: 10.2174/0929867013372058. Curr Med Chem. 2001. PMID: 11562279 Review.
[Progress in cancer treatment with histone deacetylase inhibitor].
Dong M, Hu XS, Chen SS, Xing PY, Feng FY, Shi YK. Dong M, et al. Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):481-5. Zhonghua Zhong Liu Za Zhi. 2013. PMID: 24257296 Review. Chinese. No abstract available.
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V, Huether A, Höpfner M, Schuppan D, Scherübl H. Baradari V, et al. Endocr Relat Cancer. 2006 Dec;13(4):1237-50. doi: 10.1677/erc.1.01249. Endocr Relat Cancer. 2006. PMID: 17158768
Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Gimsing P. Gimsing P. Expert Opin Investig Drugs. 2009 Apr;18(4):501-8. doi: 10.1517/13543780902852560. Expert Opin Investig Drugs. 2009. PMID: 19335278

See all similar articles

Cited by

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Yardley DA, et al. J Clin Oncol. 2013 Jun 10;31(17):2128-35. doi: 10.1200/JCO.2012.43.7251. Epub 2013 May 6. J Clin Oncol. 2013. PMID: 23650416 Free PMC article. Clinical Trial.
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Ikeda M, Ohno I, Ueno H, Mitsunaga S, Hashimoto Y, Okusaka T, Kondo S, Sasaki M, Sakamoto Y, Takahashi H, Hara R, Kobayashi S, Nakamura O, Morizane C. Ikeda M, et al. Invest New Drugs. 2019 Feb;37(1):109-117. doi: 10.1007/s10637-018-0634-5. Epub 2018 Jul 11. Invest New Drugs. 2019. PMID: 29995287 Clinical Trial.
Selective Raf inhibition in cancer therapy.
Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Khazak V, et al. Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. doi: 10.1517/14728222.11.12.1587. Expert Opin Ther Targets. 2007. PMID: 18020980 Free PMC article. Review.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE. Noonan AM, et al. Clin Cancer Res. 2013 Jun 1;19(11):3095-104. doi: 10.1158/1078-0432.CCR-13-0109. Epub 2013 Apr 15. Clin Cancer Res. 2013. PMID: 23589175 Free PMC article.
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. Yeo W, et al. J Clin Oncol. 2012 Sep 20;30(27):3361-7. doi: 10.1200/JCO.2011.41.2395. Epub 2012 Aug 20. J Clin Oncol. 2012. PMID: 22915658 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

G0501019/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information